| 生物活性 |
α-FMH (α-Fluoromethylhistidine) is an orally effective histidine decarboxylase inhibitor that depletes histamine in enterochromaffin-like (ECL) cells, reduces the number and volume density of secretory vesicles in ECL cells without affecting histamine storage in mast cells, abolishes Omeprazole (MS-S71685)-induced ECL cell vacuolation, and reduces gastrin-evoked histamine efflux from ECL cells, while not altering ECL cell granule characteristics, Omeprazole-induced ECL cell hypertrophy, gastrin-evoked pancreastatin-like immunoreactivity efflux, or histamine- or vagal stimulation-induced gastric acid secretion, and additionally inhibits basal and gastrin-stimulated gastric acid secretion and reduces gastrin+IBMX (MS-X84938)-induced acid output, but does not directly affect acid production in isolated parietal cells. |
体内研究 (In Vivo) |
α-FMH (3 mg/kg/h;皮下持续输注,6 周) 可耗竭雌性 Sprague-Dawley 大鼠的 ECL 细胞组胺,减少 ECL 细胞分泌囊泡和微囊泡的数量,并改变分泌囊泡的大小,但不影响 ECL 细胞的肥大或颗粒超微结构。 α-FMH (3 mg/kg/h;皮下持续输注,6 周) 可耗竭 ECL 细胞组胺,消除奥美拉唑诱导的 ECL 细胞空泡形成,降低 ECL 细胞分泌囊泡和微囊泡的数量及体积密度,但对奥美拉唑诱导高胃泌素血症的雌性 Sprague-Dawley 大鼠中奥美拉唑引起的 ECL 细胞肥大或颗粒超微结构无影响。 α-FMH (3 mg/kg/h;皮下注射;24 h) 可使小鼠泌酸黏膜组胺水平降低约 65%,使 ECL 细胞分泌小泡消耗约 84%,并使血浆胃泌素水平升高 130%。 α-FMH (3 mg/kg/h;皮下注射;24 h) 可使大鼠泌酸黏膜组胺水平降低约 83%,使 ECL 细胞分泌小泡耗竭约 88%,使血浆胃泌素水平升高 143%,且对胃泌酸区其他内分泌细胞类型无影响。 α-FMH (3 mg/kg/h;皮下注射;24 h) 可使仓鼠泌酸黏膜组胺水平降低约 91%,使 ECL 细胞分泌小泡耗竭约 89%,并使 ECL 细胞轮廓大小减小约 33%,且对血浆胃泌素水平无影响。 α-FMH (5 mg/kg/h;s.c.;持续给药;24 小时) 通过不可逆抑制 HDC 使雄性 Sprague-Dawley 大鼠泌酸黏膜组胺耗竭 80%,但不改变其泌酸黏膜胰抑素-LI 的浓度。 α-FMH (3-5 mg/kg/h;皮下注射、口服;持续输注、单次给药;给药 2-6 天、测试前 2 小时) 可使雌性 Sprague-Dawley 大鼠的泌酸黏膜组胺水平降低 80%,抑制超过 60%的基础胃酸分泌,几乎完全消除 gastrin-17 刺激的胃酸分泌,但不会改变组胺刺激或迷走神经诱导 (胰岛素或幽门结扎) 的胃酸分泌。
| Animal Model: |
Ross 308 (5 days old, food-deprived for 3 hours prior to injection) |
| Dosage: |
250 nmol (alone); 250 nmol (co-injected with 10 μg oxytocin) |
| Administration: |
i.c.v.; single injection |
| Result: |
Had no significant effect on cumulative food intake compared to the control group at 30, 60, or 120 minutes post-injection. Significantly attenuated the hypophagic effect of oxytocin at 30, 60, and 120 minutes post-injection. |
| Animal Model: |
C57BL/6 wild-type (male, 22 to 25 g weight, ischemic stroke model via 30 min middle cerebral artery occlusion followed by 24 h reperfusion, preceded by 3 h normobaric hypoxic preconditioning with 8% O2) |
| Dosage: |
25 mg/kg |
| Administration: |
i.p.; single injection; 3 hours before hypoxic preconditioning |
| Result: |
Reversed the neuroprotective effects of hypoxic preconditioning, eliminating the reduction in infarct volume and improvement in neurologic deficit scores seen in untreated preconditioned wild-type mice. Aggravated the reduction in peripheral cerebral blood flow during ischemia. Prevented the hypoxia-induced increase in VEGF protein expression in the cerebral cortex. Had no effect on infarct volume when administered alone. |
| Animal Model: |
Sprague-Dawley (female, 200-225 g at study start) |
| Dosage: |
3 mg/kg per h |
| Administration: |
subcutaneous; continuous infusion; 6 weeks |
| Result: |
Depleted ECL-cell histamine content and exerted no effects on ECL cell profile, cytoplasm area, granule number, or volume density. Reduced secretory vesicle number and volume density with a decreased median diameter to 165 nm, and lowered microvesicle number without altering its volume density. Eliminated ECL cell vacuoles, reduced the secretory vesicle-to-granule ratio to 2.8, and induced large, diffuse, weakly electron-dense cores in vesicles and granules. |
| Animal Model: |
Sprague-Dawley (6 months to 1 year-old male, healthy, free of pulmonary infection) |
| Dosage: |
0.2 mg/100 g; 0.5 mg/100 g; 1.0 mg/100 g |
| Administration: |
i.v.; single dose |
| Result: |
Determined the 50% inhibitory dose (ED50) for inhibition of mast cell histidine decarboxylation activity as 0.07 mg/100 g. Reduced histamine formation to ~18,000 cpm (×103 cpm/105 mast cells) at 0.2 mg/100 g dose. Reduced histamine formation to ~8,000 cpm (×103 cpm/105 mast cells) at 0.5 mg/100 g dose. Reduced histamine formation to ~1,000 cpm (×103 cpm/105 mast cells) at 1.0 mg/100 g dose.
|
| Animal Model: |
Sprague-Dawley (6 months to 1 year-old male, healthy, free of pulmonary infection) |
| Dosage: |
0.5 mg/100 g (i.v.); 2.0 mg/100 g (s.c.) |
| Administration: |
i.v.; single dose; s.c.; single dose |
| Result: |
Caused near-complete inhibition of histidine decarboxylation at 2 hours, with recovery to ~50% of baseline activity by 6 hours and full recovery. Caused near-complete inhibition at 2 hours, with recovery to only ~20,000 cpm (×103 cpm/105 mast cells). |
| Animal Model: |
Sprague-Dawley (6 to 7-week-old male, healthy, free of pulmonary infection) |
| Dosage: |
1.07 mg/100 g per day |
| Administration: |
s.c.; continuous infusion; up to 6 days |
| Result: |
Reduced histamine formation to ~15,000 cpm (×103 cpm/105 mast cells) by day 1. Reduced histamine formation to ~3,000 cpm (×103 cpm/105 mast cells) by day 2. Maintained histamine formation at ~3,000 cpm (×103 cpm/105 mast cells) through day 6, sustaining inhibition below 10% of normal activity. |
| Animal Model: |
Sprague-Dawley (6 to 7-week-old male, healthy, free of pulmonary infection) |
| Dosage: |
2 mg/100 g (priming); 0.9 mg/100 g per day (infusion); 2 mg/100 g (priming); 1.8 mg/100 g per day (infusion) |
| Administration: |
i.v.; single priming dose; s.c.; continuous infusion; 14 days |
| Result: |
Reduced peritoneal histamine‑forming activity in a dose‑dependent manner after 14‑day administration. Stabilized peritoneal cell histamine content at near‑baseline levels at both doses and blocked the marked histamine elevation observed in untreated controls. Produced body weight gains comparable to untreated controls. |
| Animal Model: |
Sprague-Dawley (6 to 7-week-old male, healthy, free of pulmonary infection, mast cell histamine depletion induced by Polymyxin B (MS-X66012)) |
| Dosage: |
2 mg/100 g (priming); 0.9 mg/100 g per day (infusion); 2 mg/100 g (priming); 1.8 mg/100 g per day (infusion) |
| Administration: |
i.v.; single priming dose; s.c.; continuous infusion; 14 days |
| Result: |
Maintained peritoneal cell histamine content at 4.6 μg at 0.9 mg/100 g per day dose after 14 days. Maintained peritoneal cell histamine content at 2.4 μg at 1.8 mg/100 g per day dose after 14 days. |
| Animal Model: |
ddy mice (male, 8 weeks old, 22 g) |
| Dosage: |
1 mg/kg; 5 mg/kg; 10 mg/kg; 25 mg/kg; 50 mg/kg; 100 mg/kg |
| Administration: |
i.p.; single dose |
| Result: |
Reduced brain, fundic stomach, and skin HDC activity to 10% of control at 5, 10, and 50 mg/kg within 4 h, respectively. Dose-dependently decreased brain and stomach histamine to 40-50% of control, without affecting skin histamine. Rapidly suppressed HDC activity in all three tissues within 1 h at 25 mg/kg. Sustained brain HDC inhibition for 12 h (full recovery by 96 h); stomach HDC recovered by 48 h; skin HDC remained low for 48 h. Lowered brain histamine to 50% for ≥ 48 h and stomach histamine to 40% within 8 h, while skin histamine was unchanged for 48 h. |
|